Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis
eLife · 2024
DOI: 10.7554/elife.87288 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Toyoshi Yanagihara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Neoplasms, Pneumonia, Drug-Related Side Effects and Adverse Reactions, Lung Diseases, Interstitial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Kakihara Foundation, Boehringer Ingelheim Japan, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Anticancer treatments can result in various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity in the lung. One of the major opportunistic infections is Pneumocystis jirovecii pneumonia (PCP), which can cause severe respiratory complications and high mortality rates. Cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs). Nonetheless, the differentiation of these diseases can be difficult, and the pathogenic mechanisms of such diseases are not yet fully understood. To better comprehend the immunophenotypes, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with PCP, cytotoxic drug-induced ILD (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers. In PCP, we observed an expansion of the CD16 + T cell population, with the highest CD16 + T proportion in a fatal case. In ICI-ILD, we found an increase in CD57 + CD8 + T cells expressing immune checkpoints (TIGIT + LAG3 + TIM-3 + PD-1 + ), FCRL5 + B cells, and CCR2 + CCR5 + CD14 + monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Respiratory Medicine, NHO Fukuoka National Hospital, Fukuoka, Japan.
- Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
- Division of Immunology and Genome Biology, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Toyoshi Yanagihara, Kentaro Hata, Kazufumi Kunimura
Förderung
- The Kakihara Foundation
- Boehringer Ingelheim Japan
- Japan Agency for Medical Research and Development
Zitieren
APA
Yanagihara, T., Hata, K., Matsubara, K., Kunimura, K., Suzuki, K., Tsubouchi, K., Ikegame, S., Baba, Y., Fukui, Y., & Okamoto, I. (2024). Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis. eLife. https://doi.org/10.7554/elife.87288
Vancouver
Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K, et al. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis. eLife. 2024. doi:10.7554/elife.87288
BibTeX
@article{Yanagihara2024,
author = {Yanagihara, Toyoshi and Hata, Kentaro and Matsubara, Keisuke and Kunimura, Kazufumi and Suzuki, Kunihiro and Tsubouchi, Kazuya and Ikegame, Satoshi and Baba, Yoshihiro and Fukui, Yoshinori and Okamoto, Isamu},
title = {Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.87288}
}
EUVIMED